Abstracts tagged "Pediatric rheumatology and systemic lupus erythematosus (SLE)"

Abstract Number: 471 • 2018 ACR/ARHP Annual Meeting
Early Signs of Diastolic Impairment in Children with Incident Systemic Lupus Erythematosus
Joyce C. Chang^1,2, Brian R. White³, Matthew D. Elias³, Rui Xiao⁴, Andrea M. Knight^5,6,7, Pamela F. Weiss^8,9,10 and Laura M. Mercer-Rosa^3,7, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸Center for Clinical Epidemiology and Biostastistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁹Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The timing and etiology of diastolic impairment in pediatric-onset systemic lupus erythematosus (pSLE) are poorly understood, and the role of screening echocardiography remains unclear.…
Abstract Number: 472 • 2018 ACR/ARHP Annual Meeting
Libman Sacks Endocarditis in Pediatric Systemic Lupus Erythematosus: Clinical Features and Complications
Marla Guzman, Meiqian Ma, B. Anne Eberhard and Joyce Hui-Yuen, Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Libman-Sacks endocarditis (LSE) is a rare manifestation of pediatric-onset systemic lupus erythematosus (pSLE). It is difficult to differentiate LSE from infective endocarditis (IE) in immunosuppressed…
Abstract Number: 1846 • 2018 ACR/ARHP Annual Meeting
Menarchal Status at Diagnosis and Final Height in Females with Childhood-Onset Systemic Lupus Erythematosus
Watchareewan Sontichai¹, Daniela Dominguez¹, Lawrence Ng¹, Deborah M. Levy¹, Jonathan Wasserman², Earl Silverman¹ and Linda Hiraki¹, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: The diagnosis of systemic lupus erythematosus (SLE) in childhood affects growth due to disease and therapy. To date, there are few studies of final…
Abstract Number: 1847 • 2018 ACR/ARHP Annual Meeting
Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics
Tamar Rubinstein¹, Marija Dionizovik-Dimanovski², Chelsey Smith³, Raphael Kraus⁴, Jordan T. Jones⁵, Julia Harris⁶, Martha Rodriguez⁷, Lauren Faust⁸, Beth Rutstein⁸, Rebecca Puplava⁹, Melissa Tesher⁹, Alaina M. Davis¹⁰, Karen Onel¹¹, Sangeeta Sule¹², Emily von Scheven¹³ and Andrea M. Knight¹⁴, ¹Pediatric Rheumatology, Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, NY, ²Pediatric Rheumatology, Children's Hospital at Montefiore, Bronx, NY, ³Children's Mercy Kansas City, Kansas City, MO, ⁴Children's Hospital at Montefiore, Bronx, NY, ⁵University of Kansas, Kansas City, KS, ⁶Children's Mercy - Kansas City, Kansas City, MO, ⁷Riley Children’s Hospital at Indiana, Indianapolis, IN, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Chicago Medicine, Chicago, IL, ¹⁰Division of Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, TN, ¹¹Hospital for Special Surgery, New York, NY, ¹²Pediatrics, Johns Hopkins University, Baltimore, MD, ¹³Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁴Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Despite high rates of depression and anxiety in pediatric lupus, standardized mental health screening is not routinely practiced by pediatric rheumatologists. Our objectives were…
Abstract Number: 2110 • 2018 ACR/ARHP Annual Meeting
Association of Systemic Lupus Erythematosus (SLE) Genetic Susceptibility Loci with Lupus Nephritis in Children and Adults with SLE
Declan Webber¹, Jingjing Cao², Daniela Dominguez³, Dafna D Gladman⁴, Deborah M. Levy⁵, Lawrence Ng³, Andrew Paterson³, Zahi Touma⁶, Murray Urowitz⁷, Joan E. Wither⁸, Earl Silverman⁵ and Linda Hiraki⁹, ¹Department of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Genetics & Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic, autoimmune disease. Genome-wide association studies (GWAS) have identified multiple risk SNPs in HLA and non-HLA gene…
Abstract Number: 2867 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Hermine I. Brunner¹, Carlos Abud-Mendoza², Diego I. Viola³, Inmaculada Calvo⁴, Deborah M. Levy⁵, Julia Calderon Gallegos⁶, Manuel Ferrandiz⁷, Vyacheslav Chasnyk⁸, Vladmir Keltsev⁹, Jordi Anton¹⁰, Maria Paz¹¹, Michael Shishov¹², Alina Lucica Boteanu¹³, Michael Henrickson¹⁴, Damon Bass¹⁵, Kenneth Clark¹⁶, Anne Hammer¹⁵, Beulah Ji¹⁶, David Roth¹⁵, Herbert Struemper¹⁷, Mei-Lun Wang¹⁸, Alberto Martini¹⁹, Daniel J Lovell²⁰ and Nicola Ruperto¹⁹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosy, Mexico, ³CAICI Institute, Rosario City, Santa Fe State, Argentina, ⁴Hospital Universitario La Fe, Valencia, Spain, ⁵Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ⁶Instituto de Ginecologia y Reproduccion, Santiago De Surco, Peru, ⁷Instituto Nacional de Salud del Nino, Lima, Peru, ⁸St Petersburg State Pediatric Medical Academy, St Petersburg, Russian Federation, ⁹City Clinical Hospital No.5, Tolyatti, Russian Federation, ¹⁰SJD Barcelona Children’s Hospital, Barcelona, Spain, ¹¹Clinica Anglo Americana, Lima, Peru, ¹²Phoenix Children's Hospital, Phoenix, AZ, ¹³University Hospital Ramón y Cajal, Madrid, Spain, ¹⁴Cincinnati Children’s Medical Center, Cincinnati, OH, ¹⁵GlaxoSmithKline, Philadelphia, PA, ¹⁶GlaxoSmithKline, Stevenage, United Kingdom, ¹⁷GlaxoSmithKline, Research Triangle Park, NC, ¹⁸GlaxoSmithKline, Collegeville, PA, ¹⁹Universita di Genova Pediatria II, Genova, Italy, ²⁰Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Belimumab (BEL) is approved in adults with active systemic lupus erythematosus (SLE). There are no approved biologic therapies for pediatric patients with childhood-onset SLE…
Abstract Number: 460 • 2018 ACR/ARHP Annual Meeting
Immunomodulatory Medication Use for Youth with Newly-Diagnosed Systemic Lupus Erythematosus
Alaina M. Davis¹, Marisa S. Klein-Gitelman², Jennifer Faerber³, Hannah Katcoff⁴, Zuleyha Cidav⁵, David Mandell⁶ and Andrea M. Knight⁷, ¹Division of Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Nashville, TN, ²Division of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/Northwestern University, Chicago, IL, ³Division of General Pediatrics, Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴Center for Pediatric Clinical Effectiveness, The Children’s Hospital of Philadelphia, Philadelphia, PA, ⁵Perelman School of Medicine, Center for Mental Health Policy and Services Research, University of Pennsylvania, Philadelphia, PA, ⁶Psychiatry and Pediatrics, Center for Mental Health Policy and Services Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁷Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: To examine immunomodulatory medication use for youth with systemic lupus erythematosus (SLE) during their first year of care. Methods: We conducted a retrospective cohort…
Abstract Number: 1266 • 2017 ACR/ARHP Annual Meeting
Geographic Variation in Use of Echocardiography at Diagnosis and Detection of Acute Cardiac Disease in Youth with Systemic Lupus Erythematosus
Joyce C. Chang¹, Andrea M. Knight², Laura M. Mercer-Rosa³, Rui Xiao⁴ and Pamela F. Weiss⁵, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, Center for Pediatric Clinical Effectiveness & PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Child-onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with a high risk of organ damage. There are no guidelines on the use…
Abstract Number: 1270 • 2017 ACR/ARHP Annual Meeting
Comparison of Clinical and Serological Features of Juvenile and Adult-Onset Neuropsychiatric Lupus in Spanish Patients
Sandra Garrote-Corral¹, Alina Boteanu², Walter A. Sifuentes-Giraldo¹, Antía García-Fernández¹, María Luz Gámir-Gámir¹ and Antonio Zea Mendoza¹, ¹Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ²Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain
Background/Purpose: Neuropsychiatric (NP) manifestations are a main cause of morbidity and mortality in juvenile-onset systemic lupus erythematosus (jSLE). Some studies suggest that they are more…
Abstract Number: 2996 • 2017 ACR/ARHP Annual Meeting
Resilience and Transition Readiness in Pediatric SLE Patients
Jamie Lai¹, Lorene Nelson², Imelda Balboni¹, Tzielan Lee¹ and Joyce Hsu¹, ¹Pediatric Rheumatology, Stanford University, Palo Alto, CA, ²Health Research and Policy - Epidemiology, Stanford University, Palo Alto, CA
Background/Purpose: Childhood onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with high morbidity that requires long-lasting care through adulthood. Transition from pediatric to…
Abstract Number: 94 • 2017 Pediatric Rheumatology Symposium
Effects of Age and Gender on Reference Levels of Biomarkers Comprising the Pediatric Renal Activity Index for Lupus Nephritis (p-RAIL)
Michael Bennett¹, Qing Ma², Jun Ying³, Prasad Devarajan¹ and Hermine Brunner⁴, ¹Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Dept of Nephrology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that disproportionately effects women and children of minorities. Renal Involvement (lupus nephritis, or LN) with…
Abstract Number: 6 • 2017 Pediatric Rheumatology Symposium
High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth
Joyce Chang^1,2, David Mandell³ and Andrea Knight^4,5,6, ¹Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Psychiatry and Pediatrics, Center for Mental Health Policy and Services Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Center for Pediatric Clinical Effectiveness & PolicyLab, Philadelphia, PA, ⁶Division of Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Childhood-onset SLE is associated with high risk for organ damage, which may be mitigated by early diagnosis and treatment. To identify points of health…
Abstract Number: 95 • 2017 Pediatric Rheumatology Symposium
Development of Cognitive Behavioral Therapy (CBT) for Childhood-onset Systemic Lupus Erythematosus (cSLE) Treatment
Jacqueline Warner¹, Erin Moorman¹, Natoshia Cunningham², Kasha Wiley³, Allen Watts³, Susmita Kashikar-Zuck⁴ and Hermine Brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: cSLE can result in considerable decrements in health-related quality of life (HRQOL) for young patients. Youth with cSLE experience a myriad of symptoms, including…
Abstract Number: 1378 • 2016 ACR/ARHP Annual Meeting
Pentraxin-3 Level Predicts Vasculitis and Mucocutaneous Involvement in Childhood-Onset Systemic Lupus Erythematosus
Sezgin Sahin¹, Amra Adrovic¹, Kenan Barut¹, Sinem Durmus², Hafize Uzun² and Ozgur Kasapcopur³, ¹Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey, ²Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, ³Department of Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Systemic lupus erythematosus (SLE) is a persistent or remitting-relapsing autoimmune disease that handled in the context of connective tissue diseases and also vasculitides. Although…
Abstract Number: 394 • 2015 ACR/ARHP Annual Meeting
Clinical Features of Children with Silent Lupus Nephritis
Hiroyuki Wakiguchi¹, Syuji Takei^2,3, Tomohiro Kubota¹, Yuichi Yamasaki¹, Tsuyoshi Yamatou¹, Yasuhito Nerome¹, Harumi Akaike¹, Yukiko Nonaka¹, Tomoko Takezaki¹, Hiroyuki Imanaka¹ and Yoshifumi Kawano¹, ¹Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, ²School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ³Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshma, Japan
Background/Purpose: Lupus nephritis (LN) is the major findings in systemic lupus erythematosus (SLE). LN with some pathologic findings in the kidney but had normal urine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].